全文获取类型
收费全文 | 29116篇 |
免费 | 3468篇 |
国内免费 | 1024篇 |
学科分类
医药卫生 | 33608篇 |
出版年
2024年 | 62篇 |
2023年 | 768篇 |
2022年 | 859篇 |
2021年 | 2020篇 |
2020年 | 1530篇 |
2019年 | 1628篇 |
2018年 | 1479篇 |
2017年 | 1450篇 |
2016年 | 1451篇 |
2015年 | 1448篇 |
2014年 | 2265篇 |
2013年 | 2306篇 |
2012年 | 1569篇 |
2011年 | 1762篇 |
2010年 | 1468篇 |
2009年 | 1306篇 |
2008年 | 1314篇 |
2007年 | 1196篇 |
2006年 | 1102篇 |
2005年 | 934篇 |
2004年 | 805篇 |
2003年 | 681篇 |
2002年 | 579篇 |
2001年 | 544篇 |
2000年 | 362篇 |
1999年 | 303篇 |
1998年 | 247篇 |
1997年 | 193篇 |
1996年 | 207篇 |
1995年 | 201篇 |
1994年 | 188篇 |
1993年 | 150篇 |
1992年 | 149篇 |
1991年 | 143篇 |
1990年 | 106篇 |
1989年 | 114篇 |
1988年 | 79篇 |
1987年 | 81篇 |
1986年 | 65篇 |
1985年 | 65篇 |
1984年 | 71篇 |
1983年 | 39篇 |
1982年 | 52篇 |
1981年 | 49篇 |
1980年 | 33篇 |
1979年 | 45篇 |
1978年 | 33篇 |
1977年 | 29篇 |
1976年 | 26篇 |
1975年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 156 毫秒
81.
Tak Mao Chan Kai Chung Tse Colin S. O. Tang Kar Neng Lai Stephen K. N. Ho 《American journal of transplantation》2004,4(7):1103-1109
The natural history of lamivudine-resistant hepatitis B virus (HBV) infection in renal transplant recipients (RTx) is unclear, despite its increasing incidence. Twenty-nine HBsAg-positive RTx with rising HBV DNA received lamivudine therapy. The course of lamivudine-resistant HBV infection was studied prospectively. During 68.7 +/- 12.5 months of follow-up, 14 (48.3%) patients developed lamivudine resistance, at 10-35 months (mean 16.9 +/- 7.0). All showed mutant sequences at codons 552 and 528 of the YMDD motif, while 13 patients demonstrated wild-type sequence at codon 555. Lamivudine resistance was unrelated to patient demographics, HBeAg status/sero-conversion, or genotype. Following resistance, HBV DNA and alanine aminotransferase showed an initial increase followed by spontaneous gradual reduction. The subsequent peak HBV DNA was lower (1.26 +/- 1.09 x 10(9) vs. 6.26 +/- 12.23 x 10(9) copies/mL, p = 0.011), while that of alanine aminotransferase was higher (196 +/- 117 vs. 77 +/- 47 imicro/l, p = 0.005), compared with pretreatment levels. Post-resistance hepatitic flare occurred in 11 (78.6%) patients. This was transient in four (36.4%), but became chronic in six (54.5%) patients. Decompensation was noted in one patient during this flare, but all survived. We conclude that drug resistance is prevalent in lamivudine-treated RTx. Despite a lower ensuing peak viremia compared with baseline, hepatitic flare is common. While most patients have spontaneous resolution, a minority may develop potentially fatal decompensation during the preceding exacerbation. 相似文献
82.
Fahim Zaman Atta Nawabi Kenneth D Abreo Gazi B Zibari 《JSLS, Journal of the Society of Laparoendoscopic Surgeons》2005,9(3):262-265
Laparoscopic procedures continue to gain popularity over traditional open procedures for a number of abdominal and pelvic surgeries. With increasing experience, the application of this technique is rising because it provides an alternative, less invasive, approach to various surgical procedures. Herein, we report our experience with adult patients with polycystic kidney disease, requiring bilateral laparoscopic nephrectomy before renal transplantation. 相似文献
83.
Pratipal Singh Vivek Vijjan Manu Gupta Deepak Dubey Aneesh Srivastava 《International journal of urology》2007,14(6):558-560
Congenital thoracic ectopic kidney is a very rare developmental anomaly and the rarest form of all ectopic kidneys. It is usually asymptomatic and discovered incidentally on routine chest radiography. Herein we reported the first case of staghorn stone in a thoracic kidney managed successfully by percutaneous nephrolithotomy. 相似文献
84.
Sundaram Hariharan Eric P. Cohen Brahm Vasudev Rimas Orentas Raphael P. Viscidi Justin Kakela Brian DuChateau 《American journal of transplantation》2005,5(11):2719-2724
We evaluated twenty renal transplant subjects at various stages of BKV nephritis (BKVN) for BKV-specific IgG and IgM antibodies using ELISA technique and BKV-DNA using PCR. They were divided as early onset (n = 7), stabilizing (n = 3), resolved (n = 8) and late onset (n = 2) BKVN. BKV-specific antibodies and BKV-DNA were simultaneously determined. The mean BKV-specific IgG level in early onset and stabilizing BKVN were 64 and 39 EIA units, and were significantly lower than 138 EIA units seen in resolved BKVN, P = 0.007, P = 0.008. The mean BKV-specific IgM levels in stabilizing BKVN was higher than resolved BKVN (130 vs 51 EIA units), P = 0.006. Mean plasma BKV loads for each group were 955,925, 5642 and 42 copies/mL of plasma, respectively. Prospective study in six BKVN cases revealed mean IgG, IgM levels and BKV-DNA at the time of diagnosis of BKVN as 39, 110 EIA units and 586,758 copies/mL of plasma, respectively. After a mean period of 5.2 months, IgG level increased to 120 EIA units (p = 0.0058) and had no detectable viral copies in circulation. Recovery from BKVN and elimination of BKV is associated with the development of BKV-specific IgG antibodies and this provides insight into the role of humoral immunity to BKV in the pathogenesis of BKVN. 相似文献
85.
Borras Merce; Valdivielso Jose M.; Egido Ramon; Vicente de Vera Pilar; Bordalba Josep Ramon; Fernandez Elvira 《Nephrology, dialysis, transplantation》2006,21(3):789-791
86.
特异性荧光偏振免疫法监测521例肾移植后环孢素A全血浓度3275次 总被引:2,自引:0,他引:2
目的通过监测肾移植后病人环孢素A(CsA)全血浓度 ,提出CsA在三联免疫抑制用药方案中的理想治疗窗。方法用特异性荧光偏振免疫法测定CsA全血浓度 ,对521例病人监测3275次 ,按术后时间及临床表现分组比较。结果肾移植后<1 ,、1~3、3~6、6~12个月、1~2和>2年的CsA全血谷浓度的理想治疗窗应分别为250~450、200~400、150~300、100~250、100~200和100~180μg/L。结论CsA全血浓度在上述范围内 ,中毒反应和排异反应明显减少 相似文献
87.
四氧嘧啶诱发糖尿病大鼠血管紧张素的变化 总被引:1,自引:0,他引:1
实验观察了四氧嘧啶诱发糖尿病大鼠连续饲养110d后体内肾素一血管紧张素系统的变化。结果表明,血浆和心脏的血管紧张素Ⅱ含量无明显变化,而肾脏的AngⅡ含量却明显低于正常对照组。另外,心脏的心钠素(ANP)含量在糖尿病大鼠与正常对照组之间无差别,血中的糖化血红蛋白含量基本无变化。上述结果表明,糖尿病大鼠早期心脏可能无明显损伤,而肾脏的肾素一血管紧张素系统活性降低。 相似文献
88.
H. Isoniemi J. Ahonen B. Eklund K. Höckerstedt K. Salmela E. von Willebrand P. Häyry 《Transplant international》1990,3(2):92-97
We have investigated the impact of triple drug immunosuppression on the occurrence of early inflammatory episodes, as detected by fine needle aspiration biopsy, and of episodes of clinical rejection during the immediate postoperative period. The prospective component of this study includes 128 consecutive first cadaveric renal transplant recipients receiving triple drug treatment consisting of azathioprine (Aza), cyclosporin (CyA) and methylprednisolone (MP). For controls we have used three historical groups: one immunosuppressed with Aza and MP (group A), another with CyA monotherapy (group B), and the third with CyA together with MP (group C) in equivalent drug dosages. On the average, 0.8 episodes of inflammation per patient were recorded during the immediate postoperative period of 30 days with triple drug treatment. This was significantly less than the 1.3 episodes in patients receiving Aza and MP (P<0.01), the 1.7 episodes in patients on CyA monotherapy (P<0.001), or the 1.6 episodes in patients receiving CyA together with MP (P<0.001). Although the first episode of inflammation commenced concurrently in each group and the peak intensity of inflammation was the same, the mean duration of inflammation was significantly shorter-2.7 days-under triple drug treatment than the 7.8–11.7 days for controls (P<0.001). The frequency of rejection episodes under triple treatment was also significantly lower-0.2 per patient-than the 0.8 per patient in controls (P<0.001). The first rejection episode occurred later in the triple drug treatment group-on the average, on day 15.2-than in the historical controls (on days 7.7–11.7). There was, however, no difference in the duration of rejection. There were no differences in patient survival between the four groups. Graft survival was 97% at 10 weeks for triple drug-treated recipients and 79%, 68%, and 87% for first grafts in groups A, B, and C, respectively. Disregarding a minor demographic bias for the triple drugtreated group with respect to preformed antibodies and preoperative dialysis treatment, the study suggests that the triple drug protocol, in the short run, is superior to any conceivable double drug combination or CyA monotherapy. 相似文献
89.
90.
Histamine-type 2 antagonists (H2-blockers) as represented by cimentidine have been shown to adversely affect renal allograft function, particularly when coadministered
with cyclosporine, currently a major immunosuppressant. To determine whether or not a newer and more powerful H2-blocker, famotidine, would produce similar adverse effects, we assessed seven cyclosporine-treated renal allograft recipients
with regard to changes in their renal function on or off the H2-blocker over a one-week period. Neither the administration nor withdrawal of famotidine (20–40 mg/day) resulted in any significant
changes in serum creatine, BUN, urine output or cyclosporine trough levels, suggesting that famotidine can be safely administered
as an H2-blocker to cyclosporine-treated renal allograft recipients. 相似文献